Preclinical and animal experiments using HIF-1α-overexpressing ADSCs for intradiscal injection may provide a therapeutic strategy for optimizing stem cell therapy in IDD therapy. This evidence concerns the gene HIF1A and intervertebral disk degenerative disorder.